MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
发明人:
GRADILONE, Sergio A.,LARUSSO, Nicholas F.
申请号：
HK16114290.0
公开号：
HK1225964A
申请日:
2016.12.15
申请国别(地区):
HK
年份:
2017
代理人:
摘要：
An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and β-catenin phosphorylation and/or acetylation while reducing bile duct β-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.
